Sglt2 Inhibitor
Video: SGLT2 inhibitors ‘gaining momentum’ in heart failure treatment
In this video, Lynne Warner Stevenson, MD, discusses new guidelines regarding the use of SGLT2 inhibitors from the American College of Cardiology Scientific Session
Combination SGLT2, GLP-1 therapy lowers risk for adverse CV outcomes in type 2 diabetes
Combined use of an SGLT2 inhibitor and GLP-1 receptor agonist is associated with reduced odds for major adverse cardiac and cerebrovascular events and heart failure in adults with type 2 diabetes, according to study findings.
Primary care intervention increases prescriptions for SGLT2 inhibitors, GLP-1 agonists
A 30-minute educational intervention for primary care physicians increased prescribing rates of SGLT2 inhibitors and GLP-1 agonists among patients with type 2 diabetes and risk factors for atherosclerotic CVD, according to researchers.
Study shows early benefits of SGLT2 inhibitors in patients with heart failure
After 1 year of treatment, SGLT2 inhibitors were associated with a 32% lower risk for hospitalization due to heart failure, regardless of type 2 diabetes status, according to a new study in Annals of Internal Medicine.
Addition of empagliflozin improves daytime glucose in type 1 diabetes
Empagliflozin added to automated insulin delivery or predictive low-glucose suspend systems significantly benefited daytime glucose levels for people with type 1 diabetes, with no extra hypoglycemia risk, according to new data.
Early detection key to preventing chronic kidney disease for adults with diabetes
About one third of adults with diabetes has chronic kidney disease, making early detection and treatment of CKD important for improving health outcomes. However, many won’t know they have the disease until it has progressed.
Technology, unexpected study findings redefine diabetes management over 20 years
This year marks the 20th anniversary of Endocrine Today. In the 2 decades since Endocrine Today was launched, the field of diabetes has undergone immense change.
VIDEO: Benefits from SGLT2 inhibitors 'cover the whole continuum of heart failure care'
Biykem Bozkurt, MD, PhD, the Mary and Gordon Cain Chair and Professor of Medicine at Baylor College of Medicine, spoke with Healio about results from trials on HF presented at the American Heart Association Scientific Sessions.
GLP-1, SGLT2 combination therapy provides largest weight loss for women with PCOS
Combination therapy with a GLP-1 receptor agonist and an SGLT2 inhibitor may provide better weight-loss benefits than a single agent for women with polycystic ovary syndrome and obesity, according to study data.
Study shows cardiovascular benefit of SGLT2 inhibitors
Sodium-glucose cotransporter 2 inhibitors are an effective class of drugs for improving morbidity and mortality in patients with established atherosclerotic CVD or cardiovascular risk factors, researchers reported.